Cannabis-Tobacco Co-Use Treatment Study
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorMedical University of South Carolina
About this trial
The purpose of the RECLAIM study is to evaluate the effectiveness of varenicline (sometimes known as Chantix) compared to placebo (an inactive substance) for the treatment of cigarettes and cannabis (marijuana). Varenicline is not FDA approved for the combination treatment of cigarette abstinence and cannabis reduction or abstinence. All participants will also receive counseling and access to online treatment modules during a quit attempt for cigarettes and a reduction attempt for cannabis. This study is being conducted by the Medical University of South Carolina. All procedures are conducted remotely and there is no in-person visits are needed.
To qualify, participants must be 18 or older, live in South Carolina, use cigarettes and cannabis, and are interested in quitting cigarettes and reducing cannabis.
Eligibility criteria
Qualifiers
Ages 18 and over (no upper age limit)
Must smoke at least 5 tobacco cigarettes per day on at least 20 out of the past 30 days for the past 3 months
Must express interest in quitting tobacco
Must express interest in cannabis reduction and/or cessation
Disqualifiers
Any significant or acutely unstable medical, psychiatric, or substance use problem (including clinically significant disorders) that would contraindicate research, interfere with safety, compromise data integrity, or preclude consistent study participation
Pregnant or trying to become pregnant
Use of medications with smoking cessation efficacy
Regular use of e-cigarettes or other tobacco products (<10 days in the past month)
Trial design
Treatments tested in this trial
- Varenicline
- Counseling
- Psychosocial modules
Treatment groups
200 Participants
are divided into 2 treatment groupsSponsors and collaborators
Medical University of South Carolina
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov